Bibliography
- Thenappan T, Shah SJ, Rich S, et al. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007;30(6):1103-10
- Schermuly RT, Ghofrani HA, Wilkins MR, et al. Mechanisms of disease: pulmonary arterial hypertension. Nat Rev Cardiol 2011;8(8):443-55
- Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res 2006;99(7):675-91
- McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the american college of cardiology foundation task force on expert consensus documents and the american heart association developed in collaboration with the american college of chest physicians; american thoracic society, inc.; and the pulmonary hypertension association. J Am Coll Cardiol 2009;53(17):1573-619
- Caruso P, MacLean MR, Khanin R, et al. Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline. Arterioscler Thromb Vasc Biol 2010;30(4):716-23
- Caruso P, Dempsie Y, Stevens HC, et al. A role for miR-145 in pulmonary arterial hypertension: evidence from mouse models and patient samples. Circ Res 2012;111(3):290-300
- Rangrez AY, Massy ZA, Metzinger-Le Meuth V, et al. miR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells. Circ Cardiovasc Genet 2011;4(2):197-205
- Machado RD, Aldred MA, James V, et al. Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension. Hum Mutat 2006;27(2):121-32
- Ciuclan L, Bonneau O, Hussey M, et al. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;184(10):1171-82
- Davis-Dusenbery BN, Chan MC, Reno KE, et al. Down-regulation of kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J Biol Chem 2011;286(32):28097-110
- Bauer NR, Moore TM, McMurtry IF. Rodent models of pah: are we there yet? Am J Physiol Lung Cell Mol Physiol 2007;293(3):L580-2
- Meloche J, Paulin R, Provencher S, et al. Therapeutic potential of microRNA modulation in pulmonary arterial hypertension. Curr Vasc Pharmacol 2013. [Epub ahead of print]
- Sakao S, Tatsumi K, Voelkel NF. Reversible or irreversible remodeling in pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2010;43(6):629-34
- Grant JS, White K, MacLean MR, et al. MicroRNAs in pulmonary arterial remodeling. Cell Mol Life Sci 2013;70(23):4479-94
- Potus F, Graydon C, Provencher S, et al. Vascular remodeling process in pulmonary arterial hypertension, with focus on mir-204 and mir-126 (2013 Grover Conference series). Pulm Circ 2014;4(2):175-84
- Sachdeva M, Zhu S, Wu F, et al. P53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009;106(9):3207-12
- Kaur H, Babu BR, Maiti S. Perspectives on chemistry and therapeutic applications of locked nucleic acid (LNA). Chem Rev 2007;107:4672-97
- van Rooij E, Purcell AL, Levin AA. Developing microrna therapeutics. Circ Res 2012;110(3):496-507
- Gebert LF, Rebhan MA, Crivelli SE, et al. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res 2014;42(1):609-21